|Bid||6.23 x 0|
|Ask||6.24 x 0|
|Day's Range||6.17 - 6.70|
|52 Week Range||6.10 - 74.28|
|Beta (5Y Monthly)||1.33|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov. 12, 2020 - Nov. 16, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.72|
Over the past 18 months, the North American marijuana industry has struggled, and a number of popular pot stocks have been pulverized. Every next-big-thing investment contends with growing pains, and that's exactly what marijuana stocks are navigating their way through at the moment. To our north, Canada has been punished by a plethora of regulatory-based supply issues.
If you had invested $10,000 in Aurora Cannabis (NYSE: ACB) just a year ago, your initial investment would be worth a meager $851 as of Sep. 29. Canada's nationwide legalization of marijuana in Oct. 2018 was supposed to bring sweeping success to the country's pot companies. Not only did Aurora get its market dynamics wrong, but management of its existing capital will probably cause more woes for investors in the future.
Aurora Cannabis (NYSE: ACB) has lost a bit of corporate stardust. Buried in an update about its upcoming annual general meeting, the marijuana grower revealed that billionaire investor Nelson Peltz has resigned as a senior advisor to the company. In an email to Marijuana Business Daily, Aurora said without much elaboration that "[t]his change is a direct result of Mr. Peltz's decision to pursue other commitments."